ProMIS Neurosciences, Inc. (TSE:PMN – Get Rating) – Research analysts at Leede Jones Gab boosted their FY2022 earnings per share estimates for shares of ProMIS Neurosciences in a research note issued on Monday, November 14th. Leede Jones Gab analyst D. Loe now forecasts that the company will post earnings of ($1.63) per share for the year, up from their previous estimate of ($1.87). The consensus estimate for ProMIS Neurosciences' current full-year earnings is ($2.73) per share. Leede Jones Gab also issued estimates for ProMIS Neurosciences' FY2023 earnings at ($1.81) EPS, FY2024 earnings at ($1.44) EPS, FY2025 earnings at ($1.90) EPS, FY2025 earnings at ($1.90) EPS and FY2026 earnings at ($1.94) EPS.

ProMIS Neurosciences Price Performance

PMN stock opened at C$8.10 on Thursday. The stock has a 50-day moving average price of C$7.88 and a two-hundred day moving average price of C$5.69. The company has a current ratio of 5.42, a quick ratio of 4.81 and a debt-to-equity ratio of 108.33. ProMIS Neurosciences has a 1 year low of C$5.70 and a 1 year high of C$12.22. The stock has a market cap of C$69.49 million and a PE ratio of -426.32.

ProMIS Neurosciences Company Profile

(Get Rating)

ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Featured Stories

• MarketBeat: Week in Review 11/14 – 11/18
• Target's Double Bottom Might Have Just Been Confirmed
• How High Can the Fed Go? How to Trade it
• Verra Mobility Stock Has Returned Back to the Station
• Does ASML's November Rally Have Staying Power?

Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.